S, v. d. S., R, V., D, W., R, H., A, P., M, B., . . . C, B. (2025). Cost comparison analysis of onasemnogene abeparvovec and nusinersen for treatment of patients with spinal muscular atrophy type 1 in the Netherlands. The European journal of health economics : HEPAC : health economics in prevention and care, 26(6), 1101. https://doi.org/10.1007/s10198-024-01754-3
Chicago Style (17th ed.) CitationS, van der Schans, Velikanova R, Weidlich D, Howells R, Patel A, Bischof M, Postma MJ, and Boersma C. "Cost Comparison Analysis of Onasemnogene Abeparvovec and Nusinersen for Treatment of Patients with Spinal Muscular Atrophy Type 1 in the Netherlands." The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care 26, no. 6 (2025): 1101. https://doi.org/10.1007/s10198-024-01754-3.
MLA (9th ed.) CitationS, van der Schans, et al. "Cost Comparison Analysis of Onasemnogene Abeparvovec and Nusinersen for Treatment of Patients with Spinal Muscular Atrophy Type 1 in the Netherlands." The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care, vol. 26, no. 6, 2025, p. 1101, https://doi.org/10.1007/s10198-024-01754-3.
